L-type Ca++ CP α1F CRISPR/Cas9 KO Plasmid (h): sc-416338
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- L-type Ca++ CP α1F CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the L-type Ca++ CP α1F genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: L-type Ca++ CP α1F Antibody (1H6): sc-517005
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
L-type Ca++ CP α1F CRISPR/Cas9 KO Plasmid (h) | sc-416338 | 20 µg | $397.00 |
Overview
CACNA1F encodes the α1F pore-forming subunit of an L-type voltage-gated calcium channel that mediates Ca2+ influx in excitable cells and couples membrane depolarization to intracellular signaling. Channel activity shapes calcium-dependent processes including synaptic transmission, neurotransmitter release, and activity-regulated gene expression through pathways such as CaM/CaMK and calcineurin–NFAT signaling. In the human retina, CACNA1F function is particularly important for photoreceptor-to-bipolar cell neurotransmission and visual signal processing. Genetic disruption of CACNA1F has been associated with inherited retinal disorders and neurodevelopmental phenotypes, supporting its relevance for studying Ca2+ channel biology and disease mechanisms.
L-type Ca++ CP α1F CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the CACNA1F gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the CACNA1F together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the CACNA1F open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish L-type Ca++ CP α1F protein expression.
This CRISPR knockout system enables efficient generation of CACNA1F-deficient cell models for investigation of L-type Ca++ CP α1F signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting CACNA1F exon(s) critical for L-type Ca++ CP α1F function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple CACNA1F genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by L-type Ca++ CP α1F CRISPR/Cas9 KO Plasmid (h) and L-type Ca++ CP α1F CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the CACNA1F locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by L-type Ca++ CP α1F HDR Plasmid (h) and L-type Ca++ CP α1F HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by CACNA1F homology arms to support homology-directed repair at defined CACNA1F target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.